The PETAL Network represents a change in focus of ARDS clinical trials, with an emphasis on therapies to prevent ARDS in high risk patients, and for early identification and intervention in patients with established ARDS. The new network also emphasizes multidisciplinary teams, including active engagement of investigators from the Emergency Medicine Department. The University of Michigan is one of twelve clinical sites throughout the country, and will be led by Robert Hyzy, M.D. from the Division of Pulmonary and Critical Care Medicine. Other key investigators include Theodore Standiford, M.D. (Division of Pulmonary and Critical Care Medicine), Pauline Park, M.D. (Department of Surgery), and Kyle Gunnerson, M.D. (Department of Emergency Medicine). The U01 provides resources to perform 4-6 clinical trials over a seven year period of funding. Investigators at the University of Michigan have proposed two clinical trials; the first assessing the impact of growth factor administration (GM-CSF) on clinical outcomes in patients at risk for or with early ARDS, and the second trial assessing the impact of macrolide administration (azithromycin) on outcome in patients with early onset ARDS. The studies proposed will also afford the opportunity to perform molecular phenotyping of patients to correlate with treatment responses, as well as assess the influence of specific therapies on the lung microbiome during ARDS. Funding will begin in August of this year, and it is anticipated that clinical trials will begin the following year.
For more information, contact Dr. Robert Hyzy.